Engineered Mesenchymal Stem Cell/Nanomedicine Spheroid as an Active Drug Delivery Platform for Combinational Glioblastoma Therapy

• Published in: Nano letters Vol. 19; no. 3; pp. 1701 - 1705
• Main Authors: Suryaprakash, Smruthi, Lao, Yeh-Hsing, Cho, Hyeon-Yeol, Li, Mingqiang, Ji, Ha Yeun, Shao, Dan, Hu, Hanze, Quek, Chai Hoon, Huang, Dantong, Mintz, Rachel L, Bagó, Juli R, Hingtgen, Shawn D, Lee, Ki-Bum, Leong, Kam W
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 13.03.2019
• Subjects: Cell Engineering - trends; Cell Movement - drug effects; Combined Modality Therapy; Drug Delivery Systems; Glioblastoma - drug therapy; Glioblastoma - genetics; Glioblastoma - pathology; Humans; Mesenchymal Stem Cells - chemistry; Mesenchymal Stem Cells - cytology; Nanomedicine - trends; Spheroids, Cellular - chemistry; Spheroids, Cellular - transplantation; Viral Tropism - drug effects; Mesenchymal stem cell; targeted therapy; nanomedicine; glioblastoma; cell spheroid
• ISSN: 1530-6984; 1530-6992
• DOI: 10.1021/acs.nanolett.8b04697

Mesenchymal stem cell (MSC) has been increasingly applied to cancer therapy because of its tumor-tropic capability. However, short retention at target tissue and limited payload option hinder the progress of MSC-based cancer therapy. Herein, we proposed a hybrid spheroid/nanomedicine system, comprising MSC spheroid entrapping drug-loaded nanocomposite, to address these limitations. Spheroid formulation enhanced MSC’s tumor tropism and facilitated loading of different types of therapeutic payloads. This system acted as an active drug delivery platform seeking and specifically targeting glioblastoma cells. It enabled effective delivery of combinational protein and chemotherapeutic drugs by engineered MSC and nanocomposite, respectively. In an in vivo migration model, the hybrid spheroid showed higher nanocomposite retention in the tumor tissue compared with the single MSC approach, leading to enhanced tumor inhibition in a heterotopic glioblastoma murine model. Taken together, this system integrates the merits of cell- and nanoparticle- mediated drug delivery with the tumor-homing characteristics of MSC to advance targeted combinational cancer therapy.